The curated database of hedge funds that publish investor letters. Research by geography, strategy, and schools of thought.
| # | Fund | Strategy | Style | Geography | AUM | Latest Letter |
|---|---|---|---|---|---|---|
Brown Capital Management's Mid Company Fund returned -7.85% in Q2 2024, underperforming the Russell MidCap Growth index's -3.21% return. The fund faced significant headwinds from what the manager describes as a shadow recession, where many portfolio companies operate in markets experiencing recessionary demand levels despite no technical U.S. recession. Higher interest rates have particularly impacted biotech funding, hurting companies like Charles River Laboratories, which saw consecutive quarterly revenue declines for the first time since 2008-2009. Top detractors included Align Technologies, Charles River, Veeva Systems, Five9, and Paycom Software, all showing significant revenue growth deceleration from pre-pandemic levels. Contributors included Guidewire Software, which reached an inflection point in its cloud transition with 16% revenue growth, and Insulet, which delivered strong results despite GLP-1 drug concerns. The fund added Natera, a diagnostic testing company with significant market opportunities in cancer-recurrence testing. The manager maintains a long-term approach with an average holding period of seven years, expecting stabilization as economic conditions improve.
Brown Capital seeks to identify Exceptional Growth Companies with durable revenue growth, sustainable competitive advantages, and differentiated products that provide exceptional value, combining early identification with long-term patience to hold through cycles.
The manager expects sales growth for affected companies to stabilize in coming quarters, though a stronger economic backdrop is likely required for growth to meaningfully accelerate. They maintain confidence in the long-term prospects of their holdings despite current macro headwinds.
As of Jun 30, 2024
The Brown Capital Management Mid Company Fund was led by Eddie C. Brown, Chairman, CEO, and Founder of Brown Capital Management, who served as lead portfolio manager since September 30, 2002. Brown brought over 40 years of investment experience and held both CFA and CIC designations. The management team included experienced professionals Walton Pearson, Kayode Aje, CFA, Kwame Webb, CFA, and Ed Zane. Following the fund's termination in August 2024, significant team transitions occurred with Walt Pearson retiring on June 30, 2024, while the remaining Mid Company team members joined the International Team as portfolio managers effective July 15, 2024. Brown Capital Management, founded in 1983, is recognized as one of the oldest African-American-founded asset management firms in the United States and operates as 100% employee-owned with 37 employees.
Brown Capital Management employs a singular investment philosophy based on identifying Exceptional Growth Companies, ignoring traditional benchmarks, and maintaining the patience and tolerance to hold positions for years. The firm believes that a sustained commitment to a portfolio of exceptional companies will, over time, generate attractive long-term returns. The strategy emphasizes vigorous internal debate and patient investing as core components. Companies are sized by operating revenues rather than market capitalization, with the fund targeting companies with total operating revenues between $500 million and $2.5 billion at initial investment. The approach typically maintains a concentrated portfolio of 40 to 60 securities believed to have significant growth potential. CRITICAL NOTE: This fund was officially terminated on August 12, 2024.
Lead Portfolio Manager
Moderate Conviction Bullish
Market Conviction
The manager demonstrates moderate-high conviction through specific position sizing language, detailed company analysis, and explicit long-term commitment with a seven-year average holding period. They name and analyze multiple specific holdings with clear investment theses, though the diversified nature of the mid-cap fund and acknowledgment of macro uncertainties prevents a higher score.
Growth Outlook
The manager describes a shadow recession with many companies experiencing recessionary demand levels, higher interest rates creating difficult environments, and the worst biotech funding conditions in five years. However, they expect stabilization in coming quarters and maintain long-term optimism.
Risk Appetite
The fund added one new position (Natera) and removed one (Teladoc), indicating selective activity. The manager maintains existing positions despite underperformance, showing measured risk appetite with no indication of defensive positioning or cash raising.
Capital Deployment
The fund made minimal net changes with one addition (Natera) and one deletion (Teladoc), representing capital rotation rather than net deployment. No cash level changes or significant position sizing adjustments were mentioned, indicating neutral deployment activity.
Forward Guidance
The manager expects sales growth to stabilize in coming quarters but acknowledges a stronger economic backdrop is needed for meaningful acceleration. This represents a neutral stance - neither aggressive deployment nor defensive pullback.
Language Signal
Language is dominated by risk-oriented terms including shadow recession, recessionary levels of demand, difficult environment, worst funding conditions, and macro weakness. While some positive language exists around specific companies, the overall tone emphasizes challenges and headwinds.
Perceived Risk
The manager identifies multiple significant risks including shadow recession conditions, the worst biotech funding environment in five years, persistent inflation above Fed targets, and sector-specific threats like GLP-1 drugs to insulin pump demand. These risks are discussed in detail with specific impact assessments on portfolio companies.
Opportunity Density
The manager describes a challenging environment where many companies face recessionary demand levels and funding difficulties. While they added one new position, the overall tone suggests limited opportunities in the current macro environment, with growth expected to require improved economic conditions.
Time Horizon
The manager explicitly states a long-term approach with an average holding period of seven years and nearly 20% of companies held for more than 10 years. They emphasize patience and tolerance to hold through cycles, indicating a multi-year investment horizon focused on long-term company fundamentals rather than near-term catalysts.
Top Conviction Themes
Key Catalysts
Every insight in this database connects to the original source. Read the actual thesis, see the actual concerns, and make your own call.
Buyside Digest has no business relationship, partnership, agency, sponsorship, endorsement, or affiliation with Brown Capital Management Mid Company Fund or any other manager whose content appears on the Service, except where expressly stated. We do not receive Manager Content directly from managers in most cases; content is collected from publicly available sources. Managers have not necessarily reviewed, approved, authorized, or endorsed our display of their content, our editorial commentary, our metadata extraction, or our classifications. Use of a manager’s name is for accurate attribution and identification purposes only, under principles of nominative fair use.
Buyside Digest does not independently verify the regulatory status, registrations, licensing, qualifications, credentials, or professional standing of managers whose content appears on the Service. We do not represent that managers are properly registered with applicable regulatory bodies, that their content complies with applicable securities laws, or that their performance representations are accurate. Inclusion of a manager in our database is based on the publicly available nature of their content, not on our verification of their regulatory status or content compliance. Users are responsible for conducting their own due diligence on any manager.
Performance data, returns, assets under management (“AUM”), and similar figures displayed on this page are sourced from publicly available manager communications (including investor letters), public filings, or other third-party sources. Buyside Digest does not independently verify performance figures, calculate returns, or audit manager-reported data. Such figures: May be selectively reported by the manager; May use non-standard calculation methodologies; May not reflect fees, expenses, taxes, or other costs; May be inconsistent across reporting periods; May be outdated. Past performance is not indicative of future results. Performance figures should not be relied upon for investment decisions without independent verification. Users should request audited performance data directly from the manager and conduct their own due diligence.
